Vanda Pharmaceuticals Reports Q3 Revenue Growth and Raises 2026 Guidance
Vanda reported third-quarter 2026 revenue of $69.8 million, up 24% year over year, and a net loss of $22.6 million, or $0.37 per share, unchanged from a year earlier. It now expects full-year revenue to exceed $240 million.
Vanda Pharmaceuticals reported total revenues of $69.8 million for the third quarter of 2026, representing a 24% increase compared to the same period in 2025. The company recorded a net loss of $22.6 million, or $0.37 per share, which remained stable compared to the prior year. Management updated its full-year 2026 revenue guidance, now expecting total revenue to exceed $240 million. The company attributed the revenue growth to the performance of Fanapt and the early commercial contribution from NEREUS.
Operating expenses decreased by 18% sequentially as Phase III and launch-preparation activities concluded.